1-19 of 19
Katerina Politi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The New NCI Precision Medicine Trials

Lyndsay N. Harris, Charles D. Blanke, Harry P. Erba, James M. Ford, Robert J. Gray, Michael L. LeBlanc, Siwen Hu-Lieskovan, Mark R. Litzow, Selina M. Luger, Funda Meric-Bernstam, Peter J. O'Dwyer, Megan K.D. Othus, Katerina Politi, Lois E. Shepherd, Carmen J. Allegra, Helen X. Chen, S. Percy Ivy, Larissa A. Korde, Richard F. Little, Lisa M. McShane, Jeffrey A. Moscow, David R. Patton, Magdalena Thurin, Laura M. Yee, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4728–4732.
https://doi.org/10.1158/1078-0432.CCR-23-0917
Published: 01 December 2023
View article titled, The New NCI Precision Medicine Trials
Open the PDF for The New NCI Precision Medicine Trials in another window
Journal Articles

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J. Piper-Valillo, Zofia Piotrowska, Christina Falcon, Helena A. Yu, Charu Aggarwal, Dylan Scholes, Tejas Patil, Christina Nguyen, Manali Phadke, Fang-Yong Li, Joel Neal, Mark A. Lemmon, Zenta Walther, Katerina Politi, Sarah B. Goldberg
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (11): 2123–2130.
https://doi.org/10.1158/1078-0432.CCR-22-3497
Published: 01 June 2023
View article titled, Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Open the PDF for Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)

Philip C. Mack, Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick, Zenta Walther, Fred R. Hirsch, Katerina Politi, Karen Kelly, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3752–3760.
https://doi.org/10.1158/1078-0432.CCR-22-0741
Published: 01 September 2022
View article titled, Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with <em>EGFR</em>-Mutant NSCLC (SWOG S1403)
Open the PDF for Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with <em>EGFR</em>-Mutant NSCLC (SWOG S1403) in another window
Includes: Supplementary data
Journal Articles

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

Anna Truini, Jacqueline H. Starrett, Tyler Stewart, Kumar Ashtekar, Zenta Walther, Anna Wurtz, David Lu, Jin H. Park, Michelle DeVeaux, Xiaoling Song, Scott Gettinger, Daniel Zelterman, Mark A. Lemmon, Sarah B. Goldberg, Katerina Politi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6382–6391.
https://doi.org/10.1158/1078-0432.CCR-19-0780
Published: 01 November 2019
View article titled, The EGFR Exon 19 Mutant L747-A750&gt;P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
Open the PDF for The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

Ila Datar, Miguel F. Sanmamed, Jun Wang, Brian S. Henick, Jungmin Choi, Ti Badri, Weilai Dong, Nikita Mani, Maria Toki, Luis D. Mejías, Maria D. Lozano, Jose Luis Perez-Gracia, Vamsidhar Velcheti, Matthew D. Hellmann, Justin F. Gainor, Kristen McEachern, David Jenkins, Konstantinos Syrigos, Katerina Politi, Scott Gettinger, David L. Rimm, Roy S. Herbst, Ignacio Melero, Lieping Chen, Kurt A. Schalper
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4663–4673.
https://doi.org/10.1158/1078-0432.CCR-18-4142
Published: 01 August 2019
View article titled, Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
Open the PDF for Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis in another window
Includes: Supplementary data
Journal Articles

Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes

Deborah B. Doroshow, Miguel F. Sanmamed, Katherine Hastings, Katerina Politi, David L. Rimm, Lieping Chen, Ignacio Melero, Kurt A. Schalper, Roy S. Herbst
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4592–4602.
https://doi.org/10.1158/1078-0432.CCR-18-1538
Published: 01 August 2019
View article titled, Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Open the PDF for Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes in another window
Journal Articles

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

Sarah B. Goldberg, Azeet Narayan, Adam J. Kole, Roy H. Decker, Jimmitti Teysir, Nicholas J. Carriero, Angela Lee, Roxanne Nemati, Sameer K. Nath, Shrikant M. Mane, Yanhong Deng, Nitin Sukumar, Daniel Zelterman, Daniel J. Boffa, Katerina Politi, Scott N. Gettinger, Lynn D. Wilson, Roy S. Herbst, Abhijit A. Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1872–1880.
https://doi.org/10.1158/1078-0432.CCR-17-1341
Published: 12 April 2018
View article titled, Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Open the PDF for Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA in another window
Includes: Supplementary data
Journal Articles

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Dara L. Aisner, Lynette M. Sholl, Lynne D. Berry, Michael R. Rossi, Heidi Chen, Junya Fujimoto, Andre L. Moreira, Suresh S. Ramalingam, Liza C. Villaruz, Gregory A. Otterson, Eric Haura, Katerina Politi, Bonnie Glisson, Jeremy Cetnar, Edward B. Garon, Joan Schiller, Saiama N. Waqar, Lecia V. Sequist, Julie Brahmer, Yu Shyr, Kelly Kugler, Ignacio I. Wistuba, Bruce E. Johnson, John D. Minna, Mark G. Kris, Paul A. Bunn, David J. Kwiatkowski
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (5): 1038–1047.
https://doi.org/10.1158/1078-0432.CCR-17-2289
Published: 28 February 2018
View article titled, The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Open the PDF for The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2) in another window
Includes: Supplementary data
Journal Articles

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

Scott Gettinger, Katerina Politi
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (18): 4539–4541.
https://doi.org/10.1158/1078-0432.CCR-16-1401
Published: 15 September 2016
View article titled, PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
Open the PDF for PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? in another window
Journal Articles

Abstract B41: Restoring sensitivity to anti-EGFR-based therapy in lung adenocarcinoma by downstream modulation of the FOXO1/KLF6 transcriptional network

Jaya Sangodkar, Suzanna Katz, Tara Albano, Heather Melville, David Burstein, Katerina Politi, Analisa Difeo, Goutham Narla
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): B41.
https://doi.org/10.1158/1078-0432.TCMUSA10-B41
Published: 02 February 2016
View article titled, Abstract B41: Restoring sensitivity to anti-EGFR-based therapy in lung adenocarcinoma by downstream modulation of the FOXO1/KLF6 transcriptional network
Journal Articles

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

Valentina Pirazzoli, Deborah Ayeni, Catherine B. Meador, Basavaraju G. Sanganahalli, Fahmeed Hyder, Elisa de Stanchina, Sarah B. Goldberg, William Pao, Katerina Politi
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 426–435.
https://doi.org/10.1158/1078-0432.CCR-15-0620
Published: 14 January 2016
View article titled, Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma
Open the PDF for Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer

Deborah Ayeni, Katerina Politi, Sarah B. Goldberg
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17): 3818–3820.
https://doi.org/10.1158/1078-0432.CCR-15-1211
Published: 31 August 2015
View article titled, Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer
Open the PDF for Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer in another window
Journal Articles

Lung Cancer in the Era of Precision Medicine

Katerina Politi, Roy S. Herbst
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2213–2220.
https://doi.org/10.1158/1078-0432.CCR-14-2748
Published: 14 May 2015
View article titled, Lung Cancer in the Era of Precision Medicine
Open the PDF for Lung Cancer in the Era of Precision Medicine in another window
Journal Articles

Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer

Katerina Politi, Scott Gettinger
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5576–5578.
https://doi.org/10.1158/1078-0432.CCR-14-2306
Published: 13 November 2014
View article titled, Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer
Open the PDF for Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer in another window
Journal Articles

Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer

Ken Takezawa, Mary Ann Melnick, Greg Riely, Mark Kris, Vincent Miller, Marc Ladanyi, Katerina Politi, William Pao, Valentina Pirazzoli, Xiaoling Song, Maria Arcila, Elisa De Stanchina, Kadoaki Ohashi, Yelena Janjigian, Paula Spitzler, Caroline Nebhan
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): A23.
https://doi.org/10.1158/1078-0432.MECHRES-A23
Published: 04 March 2013
View article titled, Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer
Open the PDF for Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer in another window
Journal Articles

Abstract A18: Reduced NF1 expression in resistance to EGF receptor inhibitory drugs in lung adenocarcinoma

Elza de Bruin, Catherine Cowell, Michael Howell, Harold Varmus, Katerina Politi, Julian Downward
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): A18.
https://doi.org/10.1158/1078-0432.MECHRES-A18
Published: 04 March 2013
View article titled, Abstract A18: Reduced NF1 expression in resistance to EGF receptor inhibitory drugs in lung adenocarcinoma
Open the PDF for Abstract A18: Reduced NF1 expression in resistance to EGF receptor inhibitory drugs in lung adenocarcinoma in another window
Journal Articles

Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas

Valentina Pirazzoli, Ken Takezawa, Elisa de Stanchina, William Pao, Katerina Politi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): A38.
https://doi.org/10.1158/1078-0432.MECHRES-A38
Published: 04 March 2013
View article titled, Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas
Open the PDF for Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas in another window
Journal Articles

Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer

Katerina Politi, Thomas J. Lynch
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1490–1492.
https://doi.org/10.1158/1078-0432.CCR-11-3282
Published: 14 March 2012
View article titled, Two Sides of the Same Coin: <em>EGFR</em> Exon 19 Deletions and Insertions in Lung Cancer
Open the PDF for Two Sides of the Same Coin: <em>EGFR</em> Exon 19 Deletions and Insertions in Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B35: Activation of Putative Compensatory Pathways upon Deletion of Erbb3 in Mutant EGFR-driven Lung Cancer

Xiaoling Song, Pang-Dian Fan, Udayan Guha, David Threadgill, Harold Varmus, Katerina Politi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): B35.
https://doi.org/10.1158/1078-0432.12AACRIASLC-B35
Published: 01 February 2012
View article titled, Abstract B35: Activation of Putative Compensatory Pathways upon Deletion of <em>Erbb3</em> in Mutant <em>EGFR</em>-driven Lung Cancer
Open the PDF for Abstract B35: Activation of Putative Compensatory Pathways upon Deletion of <em>Erbb3</em> in Mutant <em>EGFR</em>-driven Lung Cancer in another window